Yohimbine

Generic Name: Yohimbine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆N_₂O_₃

CAS Number: 146-48-5

Unique Ingredient Identifier: 2Y49VWD90Q

Background: A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.

Indication: Indicated as a sympatholytic and mydriatic. Impotence has been successfully treated with yohimbine in male patients with vascular or diabetic origins and psychogenic origins.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Effects of Stress and Drug-cue Exposure (SCM)

Phase 1

Completed

Conditions: Marijuana Abuse

Interventions: Drug: Yohimbine

First Posted Date: 2017-05-16

Last Posted Date: 2024-04-23

Lead Sponsor: Wayne State University

Target Recruit Count: 12

Registration Number: NCT03154567

Locations: 🇺🇸
Tolan Park Medical Building, Detroit, Michigan, United States

Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension

Early Phase 1

Terminated

Conditions: Hypotension, Orthostatic
Hypertension
Autonomic Nervous System Diseases

Interventions: Drug: Yohimbine
Drug: Melatonin

First Posted Date: 2016-11-15

Last Posted Date: 2019-06-12

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 10

Registration Number: NCT02963181

Locations: 🇨🇦
University Hospital, London, Ontario, Canada

Influence of the Noradrenergic System on the Formation of Intrusive Memories

Not Applicable

Completed

Conditions: Intrusive Memories

Interventions: Behavioral: Stress Film
Drug: placebo
Drug: Yohimbine
Drug: Clonidine

First Posted Date: 2015-09-04

Last Posted Date: 2015-09-04

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 118

Registration Number: NCT02541071

Locations: 🇩🇪
Department of Psychiatry and Psychotherapy, Charité University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany

Noradrenergic Activity, Cognition and Major Depressive Disorder

Not Applicable

Completed

Conditions: Major Depressive Disorder
Early Life Trauma

Interventions: Drug: yohimbine
Drug: placebo

First Posted Date: 2015-06-12

Last Posted Date: 2019-05-23

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 131

Registration Number: NCT02470026

Locations: 🇩🇪
Charite University, Berlin, Germany

The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects

Not Applicable

Conditions: Pain

Interventions: Drug: Yohimbine

First Posted Date: 2012-06-18

Last Posted Date: 2012-06-18

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 20

Registration Number: NCT01621620

Locations: 🇮🇱
Tel Aviv Sourasky Medical Center, Pain Medicine Unit, Tel Aviv, Israel

Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Yohimbine

First Posted Date: 2012-05-08

Last Posted Date: 2015-01-09

Lead Sponsor: Anders Rosengren, MD PhD

Target Recruit Count: 50

Registration Number: NCT01593215

Locations: 🇸🇪
Skanes Universitetssjukhus, Malmo, Skane, Sweden

Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine

Phase 2

Completed

Conditions: Post-Traumatic Stress Disorder

Interventions: Drug: Placebo
Drug: Yohimbine

First Posted Date: 2009-12-15

Last Posted Date: 2018-02-07

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 26

Registration Number: NCT01031979

Locations: 🇺🇸
Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina, United States

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

Phase 4

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Yohimbine

First Posted Date: 2009-09-11

Last Posted Date: 2015-06-26

Lead Sponsor: Walter Ritter GmbH & Co

Target Recruit Count: 42

Registration Number: NCT00975325

Locations: 🇩🇪
SocraTec R&D GmbH, Erfurt, Germany

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

Phase 2

Completed

Conditions: Alcoholism

Interventions: Drug: Acamprosate
Drug: mCPP
Drug: Yohimbine
Drug: Saline

First Posted Date: 2008-01-31

Last Posted Date: 2012-07-03

Lead Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Target Recruit Count: 37

Registration Number: NCT00605904

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

The Effect of Yohimbine on Cocaine Cue Reactivity

Phase 2

Completed

Conditions: Cocaine Related Disorders

Interventions: Drug: Yohimbine
Drug: Placebo

First Posted Date: 2007-09-26

Last Posted Date: 2017-06-07

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 112

Registration Number: NCT00535002

Locations: 🇺🇸
Medical University of South Carolina-GCRC, Charleston, South Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy